Abstract
Purpose
Published literature on gall bladder neuroendocrine tumors (GB NETs) is limited with none reporting the role of multimodal therapy.
Methods
Patients with histologically confirmed GB NETs treated at Tata Memorial Hospital, Mumbai, from January 2010 to June 2017 were analyzed. Staging was done by contrast-enhanced computed tomography (CECT) of abdomen and chest or a positron emission topography (PET) scan. Tumor marker (CA19-9) was measured. WHO-2017 guideline was used to classify GB NETs. GB NETs were categorized as early disease (ED) (T1, T2, N0, i.e., stages I and II); locally advanced disease (LAD) (T3, T4, or N+, i.e., stage III); and metastatic disease (MD). Response to treatment was assessed with RECIST1.1 criteria.
Results
Twenty-five patients of GB NETs were identified; 19 with neuroendocrine carcinomas (NECs) and 6 with mixed adenoneuroendocrine carcinomas (MANECs). Two patients (8%) presented with ED, 9 (36%) with LAD, and 14 (56%) had MD. Those with ED underwent open revision radical cholecystectomy. Both received adjuvant chemotherapy (ACT) with six cycles of carboplatin-etoposide and were disease-free at 3 months of follow-up. Of the nine patients with LAD, six received three cycles of neoadjuvant chemotherapy (NACT) (carboplatin-etoposide) and three operated upfront. All six patients showed partial response to NACT and five underwent open radical cholecystectomy with R0 resection. All patients operated after NACT received three cycles of ACT. Their median follow-up was 7 months (range 3–22 months). Three patients with LAD developed metastasis after median disease-free survival of 5 months. The median survival in patients with MD was 12 (range 6–23) months.
Conclusions
In carefully selected patients of GB NECs, downsizing with NACT facilitates radical resection with negative margins.
Similar content being viewed by others
References
Parkin DM, Muir CS, Whelan SL et al. Cancer incidence in five continents. Vol VI. IARC scientific publications no 120. Lyon: IARC, 1992.
Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–109. https://doi.org/10.2147/CLEP.S37357.
Albores-Saavedra J, Klöppel G, Adsay NV, et al. Carcinoma of the gallbladder and extrahepatic bile ducts. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. World Health Organization classification of tumours of the digestive system. 4th ed. Geneva: WHO Press; 2010. p. 263–78.
Joel W. Karzinoid der Gallenblasse Zentral-blAllg Pathol 1929;46:1–4.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J ClinOncol. 2008;26(18):3063–72. https://doi.org/10.1200/JCO.2007.15.4377.
Lloyd RV, Osamura RY, Klöppel G, et al. WHO classification of tumours of endocrine organs. Lyon: IARC Press; 2017.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–4.
Programme NCR. Three years report of population based cancer registries; 2009–2011. Indian Council of Medical Research: New Delhi; 2013.
Edge SB, Byrd DR, Compton CC, et al. editors. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010. Gallbladder; pp. 211–17.
Eltawil KM, Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the gall bladder: an evaluation and reassessment of management strategy. J Clin Gastroenterol. 2010;44(10):687–95. https://doi.org/10.1097/MCG.0b013e3181d7a6d4.
Komminoth P, Arnold R, Capella C, et al. Neuroendocrine neoplasms of the gallbladder and extrahepatic bile ducts. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. World health organization of tumours: pathology and genetics of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010. p. 274–6.
Kamboj M, Gandhi JS, Gupta G, Sharma A, Pasricha S, Mehta A, et al. Neuroendocrine carcinoma of gall bladder: a series of 19 cases with review of literature. J Gastrointest Cancer. 2015;46(4):356–64. https://doi.org/10.1007/s12029-015-9745-9.
Eriksson B, Annibale B, Bajetta E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology. 2009;90:214–9.
Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Informed consent was obtained.
Rights and permissions
About this article
Cite this article
Kanetkar, A.V., Patkar, S., Khobragade, K.H. et al. Neuroendocrine Carcinoma of Gallbladder: A Step Beyond Palliative Therapy, Experience of 25 Cases. J Gastrointest Canc 50, 298–303 (2019). https://doi.org/10.1007/s12029-018-0070-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-018-0070-y